InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: north40000 post# 270731

Tuesday, 08/23/2016 4:00:52 PM

Tuesday, August 23, 2016 4:00:52 PM

Post# of 345997
With Opdivo trial failures and JUNO (MSK collaborator) trial failures and the ever increasing groups that realize that responders are LOW for IO treatment .( Opdivo ...Keytruda...) and the many others falling behind n this race...all mean that Dr Wolchok should be excited about Bavituximab or any other PS Targeting drug

The headlines are there waiting for the one who is allowed to advance PS Targeting

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News